Clinical trials: Invasive Carcinoma
Bladder Cancer, Epirubicin Adverse Reaction
Comparison of the Efficacy and Safety of Continuous and Single-Dose Intravesical Epirubicin Instillation
In this study, the local and systemic side effects, tumor recurrens and progression rates of single or continuous epirubicin instillation during the early postoperative period were investigated in low and intermediate risk…
- Conditions
- Bladder Cancer, Epirubicin Adverse Reaction, Superficial Bladder Cancer, Tumor Recurrence
- Trial name
- NCT05084586
- Testing
- Intravesical Solution
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Ankara Training and Research Hospital
Non-muscle Invasive Bladder Cancer
CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON)
The study consisted of 2 sequential parts. Part A assessed the safety and tolerability of CAVATAK administered via intravesical instillation in patients with non-muscle invasive bladder cancer scheduled to undergo TUR.
- Trial name
- CANON (NCT02316171)
- Testing
- CVA21, Mitomycin C
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- Viralytics
Non-muscle-invasive Bladder Cancer
Safety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Risk Non Muscle Invasive Bladder Cancer: A Prospective, Randomized Study
About 40%-80% of NMIBC recur within 6-12 months when managed with TURBT alone, and 10%-25% of the patient's progress to muscle invasive disease.
- Trial name
- NCT05626101
- Testing
- BCG, Gemcitabine
- Where
- Egypt
- Volunteers
- 280 people
- Sponsor
- Al-Azhar University
Cancer
Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant
RATIONALE: Antifungals, such as caspofungin acetate, may be effective in treating fungal infections caused by chemotherapy or stem cell transplant.
- Trial name
- NCT00110045
- Testing
- caspofungin acetate
- Where
- 13 sites in Belgium, France and 5 more
- Volunteers
- 171 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma
Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)
This phase II trial studies the effect of avelumab, gemcitabine and carboplatin before surgery compared with surgery alone in treating patients with muscle invasive bladder or upper urinary tract cancer who are not able to…
- Conditions
- Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8
- Trial name
- NCT04871529
- Testing
- Therapeutic Conventional Surgery, Avelumab, Gemcitabine Hydrochloride
- Where
- 92 sites in United States
- Volunteers
- 6 people
- Sponsor
- SWOG Cancer Research Network
Metastatic Invasive Lobular Carcinoma (mILC)
Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast Cancer
The goal of this study is to characterize early dynamic changes in ctDNA, which can aid in tailoring early therapy in patients with metastatic Invasive lobular carcinoma (ILC).
- Trial name
- LBC-Monitor (NCT06666439)
- Testing
- circulating tumor DNA (ctDNA)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Julia Foldi
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer
This phase I/Ib trial tests the safety, side effects, best dose, and effectiveness of ASTX660 (tolinapant) in combination with eribulin mesylate (eribulin) in treating patients with triple negative breast cancer that cannot be…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Locally Advanced HER2-Negative Breast Carcinoma
- Trial name
- NCT06590558
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, Liquid Biopsy
The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second Transurethral Resection of High-risk Non-muscle Invasive Bladder Cancer
High-risk non-muscle-invasive bladder cancer (NMIBC) carries a substantial risk of residual disease after initial transurethral resection of bladder tumor (TURBT).
- Trial name
- NCT07130578
- Testing
- urine tumor DNA/RNA testing
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Second Hospital
Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma
Breast Cancer WEight Loss Study (BWEL Study)
This randomized phase III trial compares whether weight loss in overweight and obese women may prevent breast cancer from coming back (recurrence).
- Conditions
- Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7
- Trial name
- NCT02750826
- Testing
- Health Education Program, Weight Loss Intervention
- Where
- 1,498 sites in United States, Canada and 2 more
- Volunteers
- 3,177 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Invasive Breast Cancer, Ductal Carcinoma in Situ
Preoperative Testing of the Anti-Progesterone Mifepristone in Early Stage Breast Cancer
The primary objective of this study is to identify the group of women with early stage breast cancer most likely to benefit from treatment with the selective progesterone receptor modulator (SPRM) mifepristone.
- Trial name
- NCT01138553
- Testing
- Mifepristone
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of California, San Diego
Benign Breast Neoplasm, Ductal Breast Carcinoma In Situ
Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors
This randomized phase II trial studies how well docosahexaenoic acid works in preventing recurrence in breast cancer survivors. Docosahexaenoic acid supplement may prevent recurrence in breast cancer survivors.
- Conditions
- Benign Breast Neoplasm, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Lobular Breast Carcinoma In Situ
- Trial name
- NCT01849250
- Testing
- Docosahexaenoic Acid
- Where
- 4 sites in United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium
RATIONALE: Drugs used in chemotherapy, such as ifosfamide, doxorubicin, gemcitabine, and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00080795
- Testing
- filgrastim, cisplatin, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- M.D. Anderson Cancer Center
Various Advanced Cancer
An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer
The purpose of this study is to determine the effectiveness and safety of Nivolumab compared to placebo in participants who have undergone radical surgery for invasive urothelial cancer.
- Trial name
- CheckMate 274 (NCT02632409)
- Testing
- Nivolumab
- Where
- 188 sites in United States, Argentina and 28 more
- Volunteers
- 709 people
- Sponsor
- Bristol-Myers Squibb
Muscle Invasive Bladder Urothelial Carcinoma
Drug Screening Using IMD in Bladder Cancer
This research study involves implanting up to 4 microdevices, each small enough to fit inside the tip of a needle, into a tumor.
- Trial name
- NCT06204614
- Testing
- Implantable Micro-Device, Methotrexate, Carboplatin
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Invasive Breast Cancer, Breast Cancer
Comparison of Intra-operative Radiotherapy With Post-operative Radiotherapy for Women With Early Breast Cancer
The purpose of this study is to evaluate whether a single fraction of radiotherapy given intra-operatively and targeted to the tissues at the highest risk of local recurrence is equivalent to standard post-operative external beam…
- Trial name
- TARGIT (NCT00983684)
- Testing
- Intrabeam, Post-operative radiotherapy
- Where
- United Kingdom
- Volunteers
- 3,451 people
- Sponsor
- University College, London
Pancreatic Ductal Adenocarcinoma
Distal Pancreatectomy, Minimally Invasive or Open, for Malignancy (DIPLOMA)
Objective: To compare MIDP with ODP regarding radical resection rate for pancreatic ductal adenocarcinoma (PDAC) in the pancreatic body or tail.
- Trial name
- DIPLOMA (NCT04483726)
- Testing
- minimally invasive distal pancreatectomy, open distal pancreatectomy
- Where
- 5 sites in France
- Volunteers
- 9 people
- Sponsor
- University Hospital, Montpellier
Bladder Cancer, Urethral Cancer
S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium
RATIONALE: Drugs used in chemotherapy, such as carboplatin, paclitaxel, gemcitabine, and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00055835
- Testing
- carboplatin, cisplatin, gemcitabine hydrochloride
- Where
- 92 sites in United States
- Volunteers
- 7 people
- Sponsor
- SWOG Cancer Research Network
Non Muscle Invasive Bladder Cancer, Urologic Cancer
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by surveillance for the treatment of participants with IR-NMIBC.
- Conditions
- Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
- Trial name
- NCT06111235
- Testing
- Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside
- Where
- 95 sites in United States, Canada
- Volunteers
- 367 people
- Sponsor
- CG Oncology, Inc.
Low-grade Serous Ovarian Carcinoma, Recurrent Invasive Borderline Serous Ovarian Cancer
Observational Retrospective Study on Treatment and Outcomes in Patients With Low-grade Serous Ovarian Cancer
The purpose of this study is to retrospectively evaluate treatments and outcomes of patients with low grade serous ovarian carcinomas in Italy.
- Trial name
- MITO 22 (NCT02408536)
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- National Cancer Institute, Naples
Non-muscle-invasive Bladder Cancer
OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer
This phase Ⅰb/Ⅱ study evaluates the safety and efficacy of OH2 for adjuvant therapy in non-muscle-invasive bladder cancer after first-line prophylactic intravesical instillation therapy.
- Trial name
- NCT05232136
- Testing
- OH2 injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Binhui Biopharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.